SCHEMBL6714030

SCHEMBL6714030

COc1ccc(C)c(NC(=O)C(c2ccccc2)N(S)C(=O)Nc2ccccc2C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
GAA P10253 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
EPHX2 P34913 1/20 0.42
MAPK3 P27361 1/20 0.41
LMNA P02545 2/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPK1 P28482 2/20 0.40
POLB P06746 1/20 0.40
LPAR1 Q92633 1/20 0.40
MAPT P10636 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715503 0.87 POLB (0.44) ALDH1A1KDM4ETDP1RAB9ANPC1
SCHEMBL6717397 0.84 LMNA (0.53) ALDH1A1KDM4ETDP1GAASMN1; SMN2
SCHEMBL6715754 0.83 MAPT (0.46) ALDH1A1KDM4ERAB9ANPC1MEN1
SCHEMBL6716817 0.82 POLB (0.42) ALDH1A1KDM4ERAB9ANPC1MEN1
SCHEMBL6714029 0.82 ALDH1A1 (0.52) ALDH1A1KDM4ETDP1GAASMN1; SMN2
SCHEMBL6717097 0.81 GAA (0.46) ALDH1A1KDM4ETDP1GAASMN1; SMN2
SCHEMBL6717048 0.81 GRIK1 (0.48) ALDH1A1KDM4EGAASMN1; SMN2RAB9A
SCHEMBL6714006 0.79 ALDH1A1 (0.45) ALDH1A1KDM4EGAASMN1; SMN2RAB9A
SCHEMBL6717563 0.79 POLB (0.43) ALDH1A1KDM4EGAASMN1; SMN2RAB9A
SCHEMBL6714154 0.79 CASR (0.47) ALDH1A1KDM4EGAASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885KDM4E 3734/4885TDP1 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.